Score Overview
PeriodNet IncomeRevenueScoreGrowthTrendConsistencyGrowthTrendConsistency
5 Years
3.7
0.70%
60%
—
-99.75%
20%
—
5 Years
Score3.7
Net Growth0.70%
Net Trend60%
Net Income Consistency—
Rev Growth-99.75%
Rev Trend20%
Revenue Consistency—
Lyell Immunopharma Inc fundamental performance
Between 2021 and 2025, revenue declined from $ 10M to $ 36K and net income went from -$ 250M to -$ 274M. Revenue increased in 20% of the years measured; net income in 60%.
Lyell Immunopharma Inc currently holds a 5-year HDB Score of 3.7 out of 10. How the HDB Score is calculated.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-08-12 | $ 14.17 | — |
1 Year2025-08-12 | $ 10.57 | 34.06% |
5 Years2021-08-12 | $ 285.60 | -95.04% |
All Time2021-06-17 | $ 337.80 | -95.81% |
| Period | Last Price2026-08-12 | 1 Year2025-08-12 | 5 Years2021-08-12 | All Time2021-06-17 |
|---|---|---|---|---|
| Price | $ 14.17 | $ 10.57 | $ 285.60 | $ 337.80 |
| Return | — | 34.06% | -95.04% | -95.81% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2026 | $ 27K | -$ 248M | $ 204M |
| 2025 | $ 36K | -$ 274M | $ 247M |
| 2024 | $ 61K | -$ 342M | $ 370M |
| 2023 | $ 130K | -$ 234M | $ 546M |
| 2022 | $ 84M | -$ 183M | $ 640M |
| IPO2021 | $ 10M | -$ 250M | $ 614M |
Explore beyond LYEL
You're looking at Lyell Immunopharma Inc. Members apply the same fundamental framework across all 3,860 companies we cover.
- Every HDB Score — 1, 5, 10, 20 and 30 years, plus all-time
- Revenue and Net Income Consistency for every period
- Rank all 3,860 companies by any metric, not just three
- Filter by sector and currency, and page through the whole list
- Track your holdings in a portfolio
$99/year $149 founding price
Unlock Holder Dashboard30-day money-back guarantee.
